Labiotech.eu

In Depth 11 Apr 2023

Is a vaccine for Parkinson’s disease possible?

Finding a truly effective treatment for Parkinson’s disease – that goes beyond simply managing symptoms – has long been a challenging task and, to this day, there are no available therapeutic options that can effectively slow or stop the underlying disease. However, research and trials to find treatments are ongoing and, as World Parkinson’s Day […]

April 11, 2023 - 9 minutesmins - By Willow Shah-Neville

News and Trends 11 Apr 2023

Sumitomo Pharma Oncology receives orphan drug designation for Ewing sarcoma treatment

Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, said the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for TP-1287, an investigational oral CDK9 inhibitor, for the treatment of Ewing sarcoma. “We are delighted to have received this designation for TP-1287 which underscores the need for additional treatment […]

April 11, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 11 Apr 2023

Calida Therapeutics launches to tackle thrombo-inflammatory disorders

Calida Therapeutics, a preclinical stage biotech company specializing in thrombo-inflammatory disorders, has announced its incorporation in Paris, France. Calida Therapeutics has already raised €2 million ($2.17 million) in seed funding from venture capital company AdBio partners. The funds will be used to conduct additional in vivo proofs of concept and select a lead candidate. Calida […]

April 11, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 11 Apr 2023

Intracellular drug delivery startup Vitarka Therapeutics raises £1.27M

Vitarka Therapeutics, which focuses on non-viral drug delivery technology, has raised £1.27 million ($1.58 million) in equity from venture capital firm SOSV, the UK Innovation & Science Seed Fund (UK12S) and grant funding from Innovate UK. Founded in 2021 by Vineeta Tripathi, Vitarka Therapeutics is developing combination medicines using RNAi therapies and a non-viral drug […]

April 11, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 5 Apr 2023

InflaRx receives emergency use authorization for critically ill COVID-19 patients treatment

InflaRx N.V., a German company developing anti-inflammatory therapeutics by targeting the complement system, has announced that Gohibic (vilobelimab) has been granted an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) for the treatment of COVID-19 in hospitalized adults. Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody that acts on […]

April 5, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 5 Apr 2023

Ginkgo Bioworks boosts gene therapy capacity with StrideBio asset acquisition

Ginkgo Bioworks has acquired StrideBio’s adeno-associated virus (AAV) capsid discovery and engineering platform assets. A secondary close is scheduled upon the transfer of certain additional in-license agreements to Ginkgo Bioworks. Ginkgo Bioworks will incorporate the assets and IP into its end-to-end AAV gene therapy development platform, allowing the company’s customers to leverage new tools to […]

April 5, 2023 - 3 minutesmins - By Jim Cornall

In Depth 5 Apr 2023

Antimicrobial peptides: a promising class to tackle antimicrobial resistance

The discovery of penicillin in 1928 by Alexander Fleming was a momentous moment in the world of healthcare, eventually leading to the development of antibiotic drugs that allowed physicians to treat illnesses and infections that were once severe and life-threatening. But our reliance on antibiotics has now led to an emerging global health problem in […]

April 5, 2023 - 8 minutesmins - By Willow Shah-Neville

News and Trends 5 Apr 2023

Cure Ventures launches with $350M to support life sciences companies

Cure Ventures, a life sciences venture capital firm focusing on company formation around groundbreaking curative technologies, has closed its inaugural fund, Cure Ventures Fund I, L.P., at its targeted hard-cap of $350 million in capital commitments. The fund is supported by a syndicate of U.S. and internationally-based investors that includes state and city public pension […]

April 5, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 5 Apr 2023

Mosaic Therapeutics closes $28M series A funding

Mosaic Therapeutics, Ltd has closed its $28 million series A funding round. The investment in this round was raised from Syncona Investment Management, Ltd, and Cambridge Innovation Capital. The company also announced the appointment of former Novartis Oncology SVP Brian Gladsden as CEO. The Series A funding will be used to further advance Mosaic Therapeutics’ pipeline […]

April 5, 2023 - 2 minutesmins - By Jim Cornall

Best in Biotech 4 Apr 2023

6 biotechs that have stepped into the protein degradation space

Protein degradation platforms have revolutionized drug discovery aimed at undruggable targets. Biopharmaceutical companies around the world have engaged in the protein degradation field, with the hope of leveraging the capabilities of these coumpounds to successfully design drugs to treat diseases like cancer and neurodegenerative disorders. The discovery of the ubiquitin and proteolysis – protein degradation […]

April 4, 2023 - 7 minutesmins - By Roohi Mariam Peter

News and Trends 4 Apr 2023

BioNTech adds antibody-drug conjugates to cancer portfolio with potential $1.5B partnership deal

BioNTech SE and Duality Biologics (Suzhou) Co. Ltd. have entered into exclusive license and collaboration agreements for two antibody-drug conjugate (ADC) assets to develop, manufacture and commercialize the two assets globally, excluding mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region. With this collaboration, ADCs will become an additional drug class in […]

April 4, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 4 Apr 2023

Alzamend pushing ahead with Alzheimer’s vaccine trial

Alzamend Neuro, Inc. has announced the initiation of a phase I/IIA clinical trial for its immunotherapy vaccine (ALZN002) to treat mild to moderate dementia of the Alzheimer’s type. The purpose of the trial is to assess the safety, tolerability, and efficacy of multiple ascending doses of Alzamend Neuro’s ALZN002 compared with that of placebo in […]

April 4, 2023 - 4 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Is a vaccine for Parkinson’s disease possible?

Sumitomo Pharma Oncology receives orphan drug designation for Ewing sarcoma treatment

Calida Therapeutics launches to tackle thrombo-inflammatory disorders

Intracellular drug delivery startup Vitarka Therapeutics raises £1.27M

InflaRx receives emergency use authorization for critically ill COVID-19 patients treatment

Ginkgo Bioworks boosts gene therapy capacity with StrideBio asset acquisition

Antimicrobial peptides: a promising class to tackle antimicrobial resistance

Cure Ventures launches with $350M to support life sciences companies

Mosaic Therapeutics closes $28M series A funding

6 biotechs that have stepped into the protein degradation space

BioNTech adds antibody-drug conjugates to cancer portfolio with potential $1.5B partnership deal

Alzamend pushing ahead with Alzheimer’s vaccine trial

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!